Question explored with the scientific record
mrna vaccines do not migrate through out the body
The short version: mRNA vaccines do migrate beyond the injection site, and the evidence shows they reach the spleen, liver, and lymph nodes in measurable amounts.
The claim that mRNA vaccines stay local is not supported by the studies retrieved. Multiple animal studies using labeled mRNA or luciferase reporters show the same pattern. After intramuscular injection, mRNA-LNP particles are detected in the draining lymph nodes, spleen, and liver within hours to days [2, 4, 6, 7]. One 2024 study in npj Vaccines found self-amplifying mRNA in the spleen at levels about 100 times higher than in the liver on day 1, and still detectable in the spleen and injection site through day 7 [2]. A 2025 study in the Journal of Nanobiotechnology reported the highest mRNA levels in blood, followed by muscle (injection site), then spleen, then liver [1]. A 2026 study designed to reduce liver uptake showed that even with a special coating to block the liver, the particles still reached the spleen and lymph nodes [7]. The idea that these particles are trapped at the injection site is contradicted by every biodistribution study in the evidence.
The mechanism is built into the design. The lipid nanoparticle is not a static depot. It is engineered to fuse with cell membranes, deliver mRNA into cells, and those cells then produce the spike protein. The protein itself can also travel. A 2025 review in Pharmaceutics describes how spike protein can be secreted from cells, carried in exosomes, and spread systemically [21]. The LNPs themselves are taken up by immune cells at the injection site, which then migrate to the lymph nodes, carrying the mRNA and the translated protein with them [3]. This is not a bug; it is how the vaccine generates a systemic immune response. But it also means the vaccine components are distributed throughout the body.
| Tissue | Detection (Day 1) | Duration of Signal |
|---|---|---|
| Injection site (muscle) | High | Detectable through day 7 [2] |
| Draining lymph nodes | High | Detectable through day 7 [2] |
| Spleen | ~100x liver level [2] | Detectable through day 7 [2] |
| Liver | Lower than spleen | Undetectable by day 3 [2] |
| Brain | Not detected | Not detected [2] |
My call: the hypothesis that mRNA vaccines do not migrate is false based on the available animal biodistribution data. The evidence is clear that they reach the spleen, lymph nodes, and liver. Confidence: high.
Sources examined 21
-
Lipid nanoparticles-mRNA based on the consensus sequences of avian coronavirus S1 and N genes protect animals against multiple viral infections
The study designs five consensus-based avian coronavirus S1/N mRNA-LNP vaccines (four dual-antigen monovalents and one pentavalent quadrivalent) targeting IBV genotypes GI19, GI13, GI7, and GVI1, demonstrates safety, biodistribution, robust immunogenicity (humoral and cellular),…
DOI: 10.1186/s12951-025-03668-5 -
Immunogenicity and biodistribution of lipid nanoparticle formulated self-amplifying mRNA vaccines against H5 avian influenza
A set of self-amplifying mRNA vaccines encoding various forms of influenza A(H5N1) hemagglutinin delivered in lipid nanoparticles elicited strong humoral and cellular immunity in mice, with membrane-anchored full-length HA outperforming secreted forms and enabling protective ant…
DOI: 10.1038/s41541-024-00932-x -
Human CD4 T cells are a functional target for lipid nanoparticle-based mRNA vaccines
Lipid nanoparticle–based mRNA vaccines efficiently transfect human and mouse lymphoid tissue cells with CD4 T cells emerging as the dominant source of translated antigen, and CD4 T cell–derived protein production is sufficient to drive SARS-CoV-2–specific antibody responses in h…
DOI: 10.1128/mbio.02254-25 -
Engineering age-adaptive mRNA lipid nanoparticle cancer vaccines via reprogramming systemic gene expression
Age-related declines in systemic mRNA translation limit distal antigen expression and adaptive immunity after mRNA-LNP vaccination in older hosts, but engineered LNP formulations or intravenous boosting can restore systemic expression and rescue antitumor immunity.
DOI: 10.64898/2026.04.11.717910 -
Coordinated Tuning of Ionizable Lipids and Formulation Redirects mRNA Vaccines Toward Lymphoid-Specific CD4 + T Cell Immunity
New ionizable lipid N4Z, when paired with formulation tuning, redirects mRNA-LNP vaccines toward lymphoid tissues and enhances early innate signaling and CD4+ T cell–driven humoral immunity, yielding protective SARS-CoV-2 immunity in mice.
DOI: 10.64898/2026.04.16.719092 -
Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids
Lyophilization of mRNA-LNP formulations using batch and continuous spin methods with 20% sucrose is feasible, but payload retention and biodistribution post-reconstitution depend on the ionizable lipid, with S-Ac7-Dog retaining encapsulated mRNA and in vivo translation, while S-…
DOI: 10.1039/d2bm02031a -
2-arm-PEG-oligocations transiently shield the liver sinusoids to mitigate off-target hepatic expression of mRNA lipid nanoparticles
Two-arm-PEG-oligocation–mediated stealth coating of the liver sinusoidal endothelium transiently reduces hepatic iLNP uptake, redirects mRNA-LNPs to the spleen, and preserves or enhances vaccine and immunotherapy efficacy while reducing liver-associated safety risks.
DOI: 10.64898/2026.04.29.721537 -
Cascade amplification of therapeutic payloads for cancer immunotherapy
A preclinical study introducing the Cascade Amplification of Therapeutic Payloads (CATP) platform that co-delivers self-amplifying mRNA and modified alphavirus capsids/envelopes in lipid nanoparticles to achieve dual-payload amplification, yielding dramatically higher intratumor…
DOI: 10.1038/s42003-025-08735-z -
Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering
Direct SAXS analysis reveals pH-dependent rearrangements in lipoplexes containing ionizable lipids and mRNA, with a conformational transition point governed by lipid type, lipid fraction, and lipid-to-mRNA (N/P) ratio, offering mechanistic insight to tune endosomal processing fo…
DOI: 10.1021/acs.langmuir.0c02446 -
DEVELOPING AI-DESIGNED LIPID NANOPARTICLES FOR TARGETED MRNA DELIVERY TO MODULATE SPECIFIC IMMUNE CHECKPOINTS IN SOLID TUMORS
AI-driven predictive modeling was used to optimize lipid nanoparticle design for targeted mRNA delivery to solid tumors, achieving higher delivery efficiency and lower off-target exposure in simulated results.
DOI: 10.71000/bjzpn396 -
Redefining LNP composition: phospholipid and sterol-driven modulation of mRNA expression and immune outcomes
Phospholipid and sterol identity in mRNA-LNPs decisively shapes delivery efficiency and immune outcomes across in vitro, in vivo, and ex vivo systems, with β-sitosterol mirroring cholesterol in vivo and DOPE boosting antibody responses but reducing in vivo expression, underscori…
DOI: 10.1039/d5pm00150a -
Solid lipid nanocarriers embedded hydrogel for topical delivery of apremilast: In-vitro, ex-vivo, dermatopharmacokinetic and anti-psoriatic evaluation
The study develops and optimizes topical solid lipid nanoparticle (SLN) embedded hydrogel for apremilast delivery using quality-by-design and Box–Behnken design, demonstrating enhanced skin permeation/retention, prolonged release, low cytotoxicity, and anti-psoriatic activity in…
DOI: 10.1016/j.jddst.2021.102442 -
Extrahepatic, cell-specific delivery of LNPs through competitive inhibition of ApoE-mediated uptake
NanoPilot is a modular IgG-based platform that blocks ApoE-LDLR–mediated liver uptake of lipid nanoparticles and redirects their payloads to target cells, achieving efficient, cell-specific transfection in vitro and in vivo.
DOI: 10.64898/2026.05.29.727812 -
Safety and efficacy assessment of an mRNA rabies vaccine in dogs, rodents, and cynomolgus macaques
An mRNA vaccine encoding the rabies virus glycoprotein (LVRNA001) delivered with lipid nanoparticles provides cross-strain protection against rabies in dogs and mice, elicits robust humoral and Th1-biased T cell responses in cynomolgus macaques, and shows favorable chronic and r…
DOI: 10.1038/s41541-024-00925-w -
mRNA vaccine for cancer immunotherapy
mRNA cancer vaccines, including SAM and non-SAM platforms, delivered via lipid-based nanoparticles and other non-viral vehicles, are a promising cancer immunotherapy platform; ongoing clinical trials (TAAs and neoantigens) demonstrate potential, while challenges remain in antige…
DOI: 10.1186/s12943-021-01335-5 -
Human collagen III mRNA therapy for effective skin rejuvenation
This study demonstrates that intradermal delivery of full-length human COL3A1 mRNA encapsulated in lipid nanoparticles produces collagen III in skin, mitigates UVB-induced oxidative stress, senescence, and dermal damage in human fibroblasts and a murine photoaging model, improve…
DOI: 10.1186/s12967-025-07351-z -
Biomaterials as vectors for the delivery of CRISPR–Cas9
Biomaterial vectors enable CRISPR–Cas9 delivery in DNA, mRNA, and protein forms, with in vivo and in vitro demonstrations, tropism and delivery optimization, and immune considerations shaping therapeutic potential.
DOI: 10.1039/c8bm01310a -
Advances in RNA Vaccines for Preventive Indications: A Case Study of a Vaccine against Rabies
This review summarizes progress with mRNA vaccines against rabies: protamine-formulated CV7201 showed acceptable safety but administration-dependent immunogenicity in phase 1, while LNP-formulated mRNA elicited stronger preclinical responses and is now advancing in human trials.
DOI: 10.3390/vaccines7040132 -
A Case of COVID mRNA Vaccine Linked Antiphospholipid Syndrome
A 22-year-old healthy male developed antiphospholipid syndrome with a large pulmonary embolus, markedly elevated triple-positive antiphospholipid antibodies, and multisystem symptoms after his second dose of an mRNA COVID vaccine, with negative COVID testing, and improved on api…
DOI: 10.33140/bscr.02.01.13 -
Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
This study shows that unmodified sequence-optimized mRNA in lipid nanoparticles, injected intramuscularly, induces protective antibody and T-cell responses in non-human primates comparable or superior to licensed inactivated vaccines, with innate immune activation and good toler…
DOI: 10.1038/s41541-017-0032-6 -
Unique Features and Collateral Immune Effects of mRNA-LNP COVID-19 Vaccines: Plausible Mechanisms of Adverse Events and Complications
A comprehensive perspective linking the broad adverse events associated with mRNA-LNP COVID-19 vaccines to intrinsic structural features of the vaccine and its lipid nanoparticle delivery system, proposing plausible mechanisms (including ribosomal translation of spike, SP secret…
DOI: 10.3390/pharmaceutics17101327